IQVIA analysis of more than 14,000 ChannelDynamics recorded promotional interactions across EU4, UK and US suggest that messaging is already moving away from basics about the availability of a new approach to weight loss, and towards labelled benefits and supporting evidence
In the SURMOUNT-1 clinical trial, participants achieved average weight reductions of 15% (5 mg dose), 19.5% (10 mg dose), and 20.9% (15 mg dose) of baseline body weight over 72 weeks
Dopamine efflux by MPTP and hydroxyl radical generation
Additionally, the effect on gastric emptying may attenuate over time with continued treatment
Wahrscheinlich spielen verbesserte Endothelfunktionen, der Gewichtsverlust, die bessere glykmische Kontrolle und der steigende Androgenspiegel zusammen